argenex (ARGX) Expected to Announce Earnings on Thursday

argenex (NASDAQ:ARGX - Get Free Report) is expected to post its Q2 2025 quarterly earnings results before the market opens on Thursday, July 31st. Analysts expect the company to announce earnings of $2.87 per share and revenue of $776.82 million for the quarter.

argenex (NASDAQ:ARGX - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported $2.58 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.32 by $0.26. The company had revenue of $1.35 billion during the quarter, compared to analyst estimates of $748.34 million. argenex had a net margin of 40.20% and a return on equity of 16.15%. On average, analysts expect argenex to post $3 EPS for the current fiscal year and $11 EPS for the next fiscal year.

argenex Trading Down 1.4%

Shares of ARGX stock traded down $8.12 during trading hours on Friday, hitting $564.59. The company's stock had a trading volume of 336,877 shares, compared to its average volume of 333,210. The company has a 50 day moving average of $563.61 and a 200 day moving average of $600.37. The stock has a market cap of $34.55 billion, a PE ratio of 34.83, a price-to-earnings-growth ratio of 1.00 and a beta of 0.37. argenex has a 12-month low of $457.42 and a 12-month high of $678.21.

Institutional Investors Weigh In On argenex

Hedge funds have recently modified their holdings of the business. Geneos Wealth Management Inc. raised its position in shares of argenex by 550.0% in the first quarter. Geneos Wealth Management Inc. now owns 117 shares of the company's stock valued at $69,000 after buying an additional 99 shares during the last quarter. Focus Partners Wealth raised its position in shares of argenex by 22.3% in the first quarter. Focus Partners Wealth now owns 400 shares of the company's stock valued at $237,000 after buying an additional 73 shares during the last quarter. AQR Capital Management LLC raised its position in shares of argenex by 32.1% in the first quarter. AQR Capital Management LLC now owns 502 shares of the company's stock valued at $297,000 after buying an additional 122 shares during the last quarter. Finally, NewEdge Advisors LLC raised its position in shares of argenex by 5,962.5% in the first quarter. NewEdge Advisors LLC now owns 1,455 shares of the company's stock valued at $862,000 after buying an additional 1,431 shares during the last quarter. 60.32% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ARGX has been the topic of several recent research reports. Morgan Stanley initiated coverage on shares of argenex in a report on Thursday, July 3rd. They issued an "overweight" rating and a $700.00 price objective on the stock. JMP Securities set a $699.00 price target on shares of argenex in a report on Wednesday, May 14th. Citigroup reissued a "buy" rating on shares of argenex in a report on Wednesday, May 21st. Guggenheim lowered their price target on shares of argenex from $1,100.00 to $1,065.00 and set a "buy" rating on the stock in a report on Friday, May 9th. Finally, Wedbush reissued an "outperform" rating and set a $715.00 price target on shares of argenex in a report on Tuesday, June 24th. Nineteen research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, argenex currently has an average rating of "Buy" and an average target price of $728.06.

argenex Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.